Article may be outdated

This article is 3 days old. Some details may have changed since publication.

HCPLive·4 min read·hard

Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect Analysis

V
Victoria Johnson
Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect Analysis
✦AI Summary

A post hoc indirect analysis presented at the ACAAI 2026 meeting suggests that Omalizumab and remibrutinib show similar early efficacy in treating chronic spontaneous urticaria. Both drugs demonstrated improvements in disease activity scores compared to placebo within the first 14 days of treatment.

Why it matters

Comparing the speed of efficacy for chronic condition treatments is vital for improving patient quality of life and informing clinical prescription choices.

✦Dive DeeperCreate a free account to unlock

Omalizumab produced early improvements in disease activity vs placebo in chronic spontaneous urticaria (CSU), and these appeared similar to remibrutinib over the first 14 days of treatment in a post hoc indirect comparison presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, held November 12 to 16, 2026.1

Both agents are approved for CSU in patients who remain symptomatic despite H1-antihistamines. Omalizumab is an anti-IgE antibody, and remibrutinib is an oral Bruton's tyrosine kinase inhibitor.1 Omalizumab response at week 12 is well established, and up to 24% of patients achieve complete response by week 4.1,4

"Given the impact of CSU on patient quality of life, fast response to treatment is an important consideration," wrote Shyam Joshi, MD, of Oregon Health & Science University, and colleagues.1

Early omalizumab response vs placebo in ASTERIA I/II

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in